Skip to main content
Top
Published in: Clinical Rheumatology 7/2007

01-07-2007 | Original Article

Absence of antibody to cyclic citrullinated peptide in sera of non-arthritic patients with chronic hepatitis B virus infection

Authors: Sang-il Lee, Wan Hee Yoo, Hee Jin Yun, Dal Sik Kim, Hye Soo Lee, Sam Im Choi, Ji An Hur, Yong Gon Cho

Published in: Clinical Rheumatology | Issue 7/2007

Login to get access

Abstract

The objective of this study was to investigate if antibody to cyclic citrullinated peptide (anti-CCP) is detected in sera of patients with chronic hepatitis B virus (HBV) infection. Serum anti-CCP and IgA, IgG, and IgM rheumatoid factor (RF) isotypes were measured by enzyme-linked immunosorbent assay on 176 non-arthritic patients with HBV infection. IgA RF, IgG RF, and IgM RF were detectable in 29.5, 21, and 18.8% of the tested sera, respectively, with a total seropositivity rate of 42.7%. Marginally elevated anti-CCP was detected in one patient (0.6%). By regression analysis, there was no statistically significant association between the serum levels of anti-CCP and serum IgA, IgG, or IgM RF (R 2 = 0.033, with respective p values of 0.224, 0.297, and 0.334). In conclusion, anti-CCP was rarely detected in non-arthritic patients with HBV infection in contrast to RF. Thus, testing for anti-CCP may be a useful tool for the diagnosis of rheumatoid arthritis in this population.
Literature
1.
go back to reference Lovy MR, Starkebaum G, Uberoi S (1996) Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 23:979–983PubMed Lovy MR, Starkebaum G, Uberoi S (1996) Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 23:979–983PubMed
3.
go back to reference Pease C, Keat A (1985) Arthritis as the main symptom of hepatitis B infection. Postgrad Med J 61:545–547PubMedCrossRef Pease C, Keat A (1985) Arthritis as the main symptom of hepatitis B infection. Postgrad Med J 61:545–547PubMedCrossRef
4.
go back to reference Willson RA (1997) Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 92:3–17PubMed Willson RA (1997) Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 92:3–17PubMed
5.
go back to reference Csepregi A, Nemesanszky E, Rojkovich B, Poor G (2001) Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link. J Rheumatol 28:474–477PubMed Csepregi A, Nemesanszky E, Rojkovich B, Poor G (2001) Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link. J Rheumatol 28:474–477PubMed
6.
go back to reference Watanabe K, Ohkubo Y, Funahashi Y et al (1991) An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers. Clin Rheumatol 10:31–37PubMedCrossRef Watanabe K, Ohkubo Y, Funahashi Y et al (1991) An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers. Clin Rheumatol 10:31–37PubMedCrossRef
7.
go back to reference Schur PH, Shmerling RH (2003) Laboratory tests in rheumatic disorders. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology 3rd edn. Mosby, New York, pp 199–213 Schur PH, Shmerling RH (2003) Laboratory tests in rheumatic disorders. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology 3rd edn. Mosby, New York, pp 199–213
8.
go back to reference Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 41:809–814CrossRef Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 41:809–814CrossRef
9.
go back to reference Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRef Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRef
10.
go back to reference Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874PubMedCrossRef Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874PubMedCrossRef
11.
go back to reference Sauerland U, Becker H, Seidel M et al (2005) Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann N Y Acad Sci 1050:314–318PubMedCrossRef Sauerland U, Becker H, Seidel M et al (2005) Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann N Y Acad Sci 1050:314–318PubMedCrossRef
12.
go back to reference Lienesch D, Morris R, Metzger A, Debuys P, Sherman K (2005) Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 32:489–493PubMed Lienesch D, Morris R, Metzger A, Debuys P, Sherman K (2005) Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 32:489–493PubMed
13.
go back to reference Wener MH, Hutchinson K, Morishima C, Gretch DR (2004) Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 50:2305–2308PubMedCrossRef Wener MH, Hutchinson K, Morishima C, Gretch DR (2004) Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 50:2305–2308PubMedCrossRef
14.
go back to reference Bombardieri M, Alessandri C, Labbadia G et al (2004) Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 6:R137–141PubMedCrossRef Bombardieri M, Alessandri C, Labbadia G et al (2004) Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 6:R137–141PubMedCrossRef
16.
go back to reference Csepregi A, Rojkovich B, Nemesanszky E, Poor G, Hejjas M, Horanyi M (2000) Chronic seropositive polyarthritis associated with hepatitis B virus-induced chronic liver disease: a sequel of virus persistence. Arthritis Rheum 43:232–233PubMedCrossRef Csepregi A, Rojkovich B, Nemesanszky E, Poor G, Hejjas M, Horanyi M (2000) Chronic seropositive polyarthritis associated with hepatitis B virus-induced chronic liver disease: a sequel of virus persistence. Arthritis Rheum 43:232–233PubMedCrossRef
17.
go back to reference Scully LJ, Karayiannis P, Thomas HC (1992) Interferon therapy is effective in treatment of hepatitis B-induced polyarthritis. Dig Dis Sci 37:1757–1760PubMedCrossRef Scully LJ, Karayiannis P, Thomas HC (1992) Interferon therapy is effective in treatment of hepatitis B-induced polyarthritis. Dig Dis Sci 37:1757–1760PubMedCrossRef
Metadata
Title
Absence of antibody to cyclic citrullinated peptide in sera of non-arthritic patients with chronic hepatitis B virus infection
Authors
Sang-il Lee
Wan Hee Yoo
Hee Jin Yun
Dal Sik Kim
Hye Soo Lee
Sam Im Choi
Ji An Hur
Yong Gon Cho
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0451-7

Other articles of this Issue 7/2007

Clinical Rheumatology 7/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine